このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Miniature In-line Respirator

First-In-Human Trial of Miniature In-Line, Pressure-Cycled, Emergency Respirator Device in Human Organ Donors

This first-in-human pilot study will test an investigational miniature breathing device called the Hope inVent. The device is a small, single-use, in-line respirator that connects to a breathing tube and uses compressed oxygen to help move air in and out of the lungs. It has no moving parts and is designed to provide short-term breathing support in situations where standard ventilators may not be available, such as emergencies, disasters, battlefield settings, transport, or ventilator shortages.

The study will enroll up to 5 brain-dead organ donors who are already receiving mechanical ventilation at the Gift of Life Donor Care Center at the Hospital of the University of Pennsylvania. Donors will only be included after authorization for organ donation and research has been obtained through standard procedures. Donors who may donate lungs or who have significant lung disease will not be included.

During the study, investigators will briefly replace the standard ventilator with the Hope inVent device for up to 15 minutes. The standard ventilator will remain immediately available, and the donor will be continuously monitored by the clinical and research teams. Investigators will measure whether the device can maintain acceptable breathing measures, including oxygen level and carbon dioxide level. They will also record breathing pressures and tidal volume, which is the amount of air delivered with each breath. If the device does not perform as expected or if any safety concern occurs, the donor will be returned immediately to the standard ventilator.

There is no direct benefit to the organ donor. Information from this study may help determine whether this type of simple, low-cost breathing device could be useful for future patients who need emergency or short-term ventilator support when standard ventilators are not available.

調査の概要

状態

まだ募集していません

詳細な説明

Study Description:

Proof of Concept pilot study to support use of a miniature in-line patient respirator for patient ventilation needs.

Objectives:

Primary Objective:

To assess the effectiveness of the miniature respirator to ventilate intubated braindead research donors while maintaining respiratory measures within acceptable range.

Secondary Objective

The miniature respirator performs as designed and tested in a lung simulator.

Endpoints:

Primary Endpoint:

A binary variable equal to 1 ("success") if both of the following criteria are met (during the placement of the test device):

  1. the respirator maintains the end tidal CO(2) between 35- and 45-mm Hg;

    and

  2. the O(2) saturation measured by pulse oximetry is > 94%.

Otherwise, the primary endpoint is equal to 0 ("failure").

Secondary Endpoints:

Binary variables equal to 1 ("success") if tidal volume and airway pressure settings (PEEP and maximum peak airway pressure) are within 30% of predicted values. Otherwise, the secondary endpoints are equal to 0 ("failure").

研究の種類

介入

入学 (推定)

5

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

  • 名前:Andrew J Mannes, M.D.
  • 電話番号:(301) 594-3427
  • メール:amannes@cc.nih.gov

研究場所

    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19104
        • Hospital of the University of Pennsylvania
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1年~100年 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

  • INCLUSION CRITERIA

    1. Diagnosis of brain death
    2. Provision of signed and dated informed consent form for organ donation and research by donor family or surrogate decisionmaker.
    3. Male or female, with no age restriction (see size exclusion).
    4. Decedent transferred to the Gift of Life at Penn Medicine Donor Care Center (study site) for routine organ donor management and organ recovery procedures.

EXCLUSION CRITERIA

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Brain-dead research donor will be excluded if their baseline CO(2) or pulse oximetry is out of the accepted range for the study (defined as end tidal CO(2) between 35- and 45-mm Hg and the O(2) saturation measured by pulse oximetry > 94%) while on optimized ventilation.

  2. Brain-dead research donors with severe respiratory disease. This may include:

    • Bullous lung disease - noted on pre-op imaging or by history.
    • h/o pneumothoraces
    • h/o severe asthma, COPD, or other significant lung disease
  3. Brain-dead research donors with morbid obesity (BMI >=40).

  4. Brain-dead research donor body weight of < 25kg.

  5. Potential Brain-dead lung transplant donors (as determined by Gift of Life Donor Program staff according to at the time of study site (Donor Care Center) admission)

  6. Intraoperative arterial blood gas values outside the range of normal for pH, PaO2, PaCO2, HCO3, O2Sat as measured in pre-device ABG (while on optimized ventilation).

Acceptable range for Arterial Blood Gas (ABG values)

Parameter - pH / Range - 7.35-7.45

Parameter - PaO2 / Range - >=75 mm Hg

Parameter - PaCO2 / Range - 35-45 mm Hg

Parameter - HCO3 / Range - 22-26 mEq/L

Parameter - SpO2 / Range - 94-100

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:デバイスの実現可能性
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Hope inVent Miniature In-line Respirator

All enrolled brain-dead organ donors who meet eligibility criteria will receive the investigational Green Hope inVent miniature in-line, pressure-cycled respirator for up to 15 minutes. Respiratory and physiologic measures will be collected before device placement while the donor is on the standard mechanical ventilator and during use of the Hope inVent device. Each donor serves as their own control; there is no separate comparator arm. The standard ventilator will remain available, and donors will be returned to standard ventilation after testing or earlier if safety or performance criteria require.

The Hope inVent is an investigational, single-use, miniature in-line respirator designed to provide short-term ventilatory support for intubated individuals. The device is a 3D-printed, pressure-cycled, gas-powered respirator with no moving parts. It connects to the endotracheal tube breathing circuit and uses compressed oxygen as its power source. In this study, only the Green Hope inVent model will be used. The device cycles between fixed pressure settings: peak inspiratory pressure of 18 cm H2O and positive end-expiratory pressure of 6 cm H2O. Enrolled brain-dead research donors will be placed on the device once for up to 15 minutes, with continuous respiratory and physiologic monitoring. The donor will then be returned to the standard mechanical ventilator.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Proportion of donors with successful ventilation and oxygenation during Hope inVent testing.
時間枠:During device use, from connection of the Hope inVent device to removal, up to 15 minutes.

Success is defined as maintaining both end-tidal carbon dioxide between 35 and 45 mm Hg and oxygen saturation by pulse oximetry greater than 94% during placement of the Hope inVent device. If either criterion is not met, or if device use is stopped early because of inadequate ventilation or oxygenation, the outcome is classified as failure.

During device use, from connection of the Hope inVent device to removal, up to 15 minutes.

二次結果の測定

結果測定
メジャーの説明
時間枠
Proportion of donors with tidal volume within 30% of predicted value
時間枠:During device use, from connection of the Hope inVent device to removal, up to 15 minutes.

Tidal volume will be measured using an in-line respiratory monitor while the donor is ventilated with the Hope inVent device. Each donor will be classified as a success if tidal volume is within 30% of the protocol-specified predicted value; otherwise, the donor will be classified as a failure.

During device use, from connection of the Hope inVent device to removal, up to 15 minutes.
Proportion of donors with positive end-expiratory pressure within 30% of predicted value
時間枠:During device use, from connection of the Hope inVent device to removal, up to 15 minutes

Positive end-expiratory pressure will be measured using an in-line respiratory monitor during Hope inVent ventilation. Each donor will be classified as a success if positive end-expiratory pressure is within 30% of the protocol-specified predicted value; otherwise, the donor will be classified as a failure.

During device use, from connection of the Hope inVent device to removal, up to 15 minutes
Proportion of donors with maximum peak airway pressure within 30% of predicted value
時間枠:During device use, from connection of the Hope inVent device to removal, up to 15 minutes

Maximum peak airway pressure will be measured using an in-line respiratory monitor during Hope inVent ventilation. Each donor will be classified as a success if maximum peak airway pressure is within 30% of the protocol-specified predicted value; otherwise, the donor will be classified as a failure.

During device use, from connection of the Hope inVent device to removal, up to 15 minutes

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Andrew J Mannes, M.D.、National Institutes of Health Clinical Center (CC)

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月9日

一次修了 (推定)

2028年12月1日

研究の完了 (推定)

2028年12月1日

試験登録日

最初に提出

2026年8月14日

QC基準を満たした最初の提出物

2026年8月14日

最初の投稿 (実際)

2026年8月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年11月3日

最終確認日

2026年8月12日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified or anonymized individual donor-level data may be shared with collaborating investigators or institutions at NIH, the University of Pennsylvania, or outside institutions, and/or submitted to NIH-designated databases, consistent with donor authorization, applicable IRB approvals, NIH policies, and federal regulations. Shared data will not include direct identifiers. If coded data are shared, the code key will not be provided to collaborators. No biospecimens will be stored or shared for future use.

IPD 共有時間枠

De-identified or anonymized individual participant data and supporting information may become available after publication of the primary study results or posting of summary results on ClinicalTrials.gov, subject to applicable consent/authorization, IRB approvals, data-use agreements, and NIH/federal requirements.

IPD 共有アクセス基準

De-identified or anonymized donor-level data may be shared with qualified investigators at NIH, the University of Pennsylvania, or other institutions upon written request to the Principal Investigator. Requests must describe the proposed scientific use, such as analyses of device performance, respiratory/physiologic outcomes, safety, or related protocol objectives. Requests will be reviewed by the study team/sponsor and shared only as permitted by donor authorization, IRB approvals, institutional policies, data-use or collaboration agreements, and NIH/federal requirements. Data may be shared with investigators/institutions with a Federalwide Assurance or operating under the Declaration of Helsinki; other sharing will require prospective IRB approval. Data may be transferred securely or submitted to an NIH-designated database. Direct identifiers and code keys will not be shared.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する